Renaissance Technologies
BBOT icon

Renaissance Technologies’s BridgeBio Oncology BBOT Stock Holding History

Renaissance Technologies’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447K Sell
58,600
-43,300
-42% -$361K ﹤0.01% 2637
2026
Q1 		$912K Buy
101,900
+27,600
+37% +$296K ﹤0.01% 2319
2025
Q4 		$930K Buy
+74,300
New +$900K ﹤0.01% 2324

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies's BBOT Position: Q2 2026 in Review

Renaissance Technologies reduced its BridgeBio Oncology (BBOT) stake by 42% in Q2 2026, selling an estimated $361K and leaving 58,600 shares worth $447K. The position accounts for ﹤0.01% of the portfolio, ranked #2637.

Renaissance Technologies first reported a position in BBOT in Q4 2025 and has held it in 3 quarters since. The position peaked at $930K in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Renaissance Technologies held 58,600 shares of BridgeBio Oncology worth $447K as of Q2 2026.
  • Renaissance Technologies sold 43,300 BridgeBio Oncology shares in Q2 2026, an estimated $361K.
  • BridgeBio Oncology made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2637 holding.
  • Renaissance Technologies first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 3 quarters since.
  • Renaissance Technologies's BridgeBio Oncology position peaked at $930K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.